Trading

Data

Solutions

Insights

Epic Sciences Stock

epicsciences.comHealthcareFounded: 2008Funding to Date: $178.39MM

Epic Sciences is a developer of novel diagnostics designed to personalize and advance the treatment and management of cancer.

Buy or sell Epic Sciences stock Learn more about Epic Sciences IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for Epic Sciences.

Register Today

Team

Management Team

Pascal Bamford Ph.D

Chief Scientific Officer and Head of Laboratory Operations

Dena Marrinucci Ph.D

Co-Founder & Member Clinical Advisory Board

Murali Prahalad Ph.D

Chief Executive Officer & President

Ryan Dittamore

Chief of Medical Innovation and Head of Translational Research Partnerships

Ian Miller JD

Chief Business Officer and General Counsel

Dave Henderson

Chief Information Officer

Board Members

Evgeny Zaytsev Ph.D

RusnanoMedInvest

Kim Kamdar Ph.D

Domain Associates

John Sage

Andrew ElBardissi MD

Deerfield Management

Peter Kuhn Ph.D

Gregory Critchfield MD

Gregory Lucier

Simon Greenwood Ph.D

Roche Venture Fund

Other companies like Epic Sciences in the Healthcare sector

Neuralink

Sector

Healthcare

Last Round Est. Valuation

$2.15B

Sector

Sector

Last Round Est. Valuation

$3.67B

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Grail

Sector

Healthcare

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$1.08B

Cytonics

Sector

Healthcare

Precision Neuroscience

Sector

Healthcare

News

FinSMEs 09/12/2018

Epic Sciences Closes $52M in Series E Financing | FinSMEs

Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing

Popular Topics

Popular Topics

Epic Sciences Stock

Register for Details